Journal of Medicinal Chemistry p. 6734 - 6750 (2019)
Update date:2022-08-15
Topics:
Wang, Qinghui
Arnst, Kinsie E.
Wang, Yuxi
Kumar, Gyanendra
Ma, Dejian
White, Stephen W.
Miller, Duane D.
Li, Wei
Li, Weimin
ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure-activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogues, most notably 10ab and 10bb. The crystal structures of 10ab and 10bb in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model. In addition, pharmacological screening suggested that 10bb has a low risk of potential off-target function.
View MoreShanghai Sunwise Chemical Co., Ltd
website:http://www.sunwisechem.com
Contact:86-021-33883180
Address:Room 10E, Building G, Westlink Center, No. 2337 Gudai Road, Minhang District, Shanghai, China PC: 201100
Contact:+86-371-86058576
Address:NO.32, Jingsan Road, Zhengzhou, China
Contact:+86-533-3112891
Address:zibo
Contact:86-571-61063068
Address:LINAN
Shanghai SMEC Trading Co., Ltd.
website:http://www.shanghaismec.com
Contact:+86-21-68811293
Address:ROOM 1101,NO.800 SHANGCHENG RD,SHANGHAI,CHINA
Doi:10.1021/jo970882t
(1997)Doi:10.1021/jo9711495
(1997)Doi:10.1016/S0020-1693(00)81368-7
(1986)Doi:10.1016/S0040-4039(97)01588-8
(1997)Doi:10.1021/jo001323g
(2001)Doi:10.1002/jhet.5570340418
(1997)